ALK(SZ:002940)2024-12-13 01:17Group 1: Financial Performance and Market Strategy - The company actively participated in the 10th batch of national drug centralized procurement, with future sales of α-keto acid raw materials dependent on the final selection results of the formulation varieties [1] - The company’s R&D expenses reached CNY 164.44 million by the end of Q3 2024, with expectations for continued high investment in R&D in the coming years [2] - The sales of the drug "Zuo Yi" were impacted by the failure to win bids in the national procurement last year and the "Four Consistencies" policy this year, but the company plans to expand its market [4] Group 2: Product Development and Clinical Trials - The NHKC-1 drug, currently in Phase III clinical trials for treating primary hypertension, could become a new product line if approved [2] - The company has initiated preliminary research on the penicillin enzyme project, which may lead to timely information disclosure if implemented [2] - The company is advancing the registration of steroid raw materials to enhance product value [2] Group 3: Competitive Landscape and Pricing Strategy - The price and competitive landscape of industrial salt will significantly impact the entire cephalosporin raw material market [2] - The sales strategy for the generic drug "Noxintan" will depend on the patent protection period of the original drug and market demand [2] - The company plans to leverage existing sales channels for hypertension products to actively explore the market for NHKC-1 [2]